Hey JC how do think these comments from marcelo fit within your understanding of the health care system regarding engagement . appreciate it.
"We saw tandem as our scientific launch, we had multiple activities during the convention, i think we could see the enthusiasm for the products and the level of questions asked, in terms of availability, when people can actually start prescribing the products, pricing was very encouraging and the feedback we received from most centers was also very important for us. tandem was a successful scientific launch.
In terms of engagement with payers, obviously weve been engaging with all payers for quite some time now. I think there is an appreciation for the low number of kids that is effected by this condition 375 kids, and as silviu mentioned this price is fair when you consider the benefits that ryoncil provides to these kids. so overall i think the discussion have been very positive, i think there is an appreciation for the burden of the disease and also an appreciation for the long term survival that ryoncil offer these patients so we are very optimistic and are looking forward to the next steps"
MSB Price at posting:
$2.52 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)